Clinical Trial Update: ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alectinib for pretreatment RET-rearranged advanced non-small cell lung cancer has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2025-03-26